CGEN saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 69 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGEN's RSI Indicator exited the oversold zone, 35 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CGEN just turned positive on October 28, 2026. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +11.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 187 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for CGEN moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CGEN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CGEN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.092) is normal, around the industry mean (3.498). P/E Ratio (5.158) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The RSI Indicator for GHRS moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 18 similar instances when the indicator left oversold territory. In 17 of the 18 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 49 cases where GHRS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for GHRS just turned positive on October 23, 2026. Looking at past instances where GHRS's MACD turned positive, the stock continued to rise in 45 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Following a +5.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where GHRS advanced for three days, in 249 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GHRS as a result. In 80 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
GHRS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GHRS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.553) is normal, around the industry mean (3.498). P/E Ratio (-18.798) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. GHRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CGEN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 20 | |
PRICE GROWTH RATING 1..100 | 60 | |
P/E GROWTH RATING 1..100 | 57 | |
SEASONALITY SCORE 1..100 | 42 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CGEN | GHRS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 85% |
| Advances ODDS (%) | 3 days ago 81% | 2 days ago 89% |
| Declines ODDS (%) | 17 days ago 88% | 7 days ago 84% |
| BollingerBands ODDS (%) | 1 day ago 87% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGEN’s FA Score shows that 1 FA rating(s) are green while GHRS’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGEN’s TA Score shows that 4 TA indicator(s) are bullish while GHRS’s TA Score has 4 bullish TA indicator(s).
CGEN (@Biotechnology) experienced а +2.96% price change this week, while GHRS (@Biotechnology) price change was -3.41% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
CGEN is expected to report earnings on Mar 09, 2027.
GHRS is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with RXRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To CGEN | 1D Price Change % | ||
|---|---|---|---|---|
| CGEN | 100% | N/A | ||
| RXRX - CGEN | 39% Loosely correlated | +1.13% | ||
| RCUS - CGEN | 37% Loosely correlated | +0.70% | ||
| ABCL - CGEN | 37% Loosely correlated | -4.09% | ||
| AXON - CGEN | 36% Loosely correlated | +4.26% | ||
| GHRS - CGEN | 36% Loosely correlated | -1.58% | ||
More | ||||
A.I.dvisor indicates that over the last year, GHRS has been loosely correlated with STTK. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if GHRS jumps, then STTK could also see price increases.
| Ticker / NAME | Correlation To GHRS | 1D Price Change % | ||
|---|---|---|---|---|
| GHRS | 100% | -1.58% | ||
| STTK - GHRS | 44% Loosely correlated | +4.12% | ||
| FDMT - GHRS | 40% Loosely correlated | +4.25% | ||
| IMRX - GHRS | 39% Loosely correlated | -1.56% | ||
| VIR - GHRS | 38% Loosely correlated | -0.15% | ||
| SANA - GHRS | 37% Loosely correlated | -5.76% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ORCX | 14.91 | 2.24 | +17.68% |
| Defiance Daily Target 2X Long ORCL ETF (ORCX) | |||
| MISL | 42.89 | 0.38 | +0.89% |
| First Trust Indxx Aerospace & Defense ETF (MISL) | |||
| INTF | 41.65 | 0.10 | +0.24% |
| iShares International Equity Factor ETF (INTF) | |||
| BAMY | 26.73 | 0.05 | +0.20% |
| Brookstone Yield ETF (BAMY) | |||
| PRIZ | 24.61 | -0.01 | -0.04% |
| Zacks Preferred Income ETF (PRIZ) | |||